Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 | O60894 | 3/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17728821 | 1.00 | RAMP1 (0.40) | RAMP1CALCRLHCRTR1HCRTR2 | |
| SCHEMBL3698338 | 1.00 | RAMP1 (0.40) | RAMP1CALCRLHCRTR1HCRTR2 | |
| SCHEMBL17728827 | 0.83 | SIGMAR1 (0.40) | RAMP1CALCRL | |
| SCHEMBL3700601 | 0.82 | CALCRL (0.41) | RAMP1CALCRL | |
| SCHEMBL17728826 | 0.82 | CALCRL (0.41) | RAMP1CALCRL | |
| SCHEMBL3703887 | 0.82 | CALCRL (0.41) | RAMP1CALCRL | |
| SCHEMBL17728829 | 0.80 | RAMP1 (0.41) | RAMP1CALCRL | |
| SCHEMBL3700283 | 0.80 | RAMP1 (0.41) | RAMP1CALCRL | |
| SCHEMBL3703415 | 0.80 | MDM2 (0.39) | — | |
| SCHEMBL16661420 | 0.79 | RAMP1 (0.44) | RAMP1CALCRLHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409916-B2 | Piperidinone carboxamide spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150005330-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-01-01 | — | — | US | disclosed |
| US-8912210-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8883807-B2 | Piperidinone carboxamide indane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140011827-A1 | PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2014-01-09 | — | — | US | disclosed |
| US-20130231358-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-09-05 | — | — | US | disclosed |
| US-8481556-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck, Sharp & Dohms, Corp. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231358-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | RAMP1 29/4885CALCRL 1/4885HCRTR1 65/4885 |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | RAMP1 37/4885CALCRL 1/4885HCRTR1 71/4885 |
| US-20150005330-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | RAMP1 37/4885CALCRL 1/4885HCRTR1 71/4885 |
| US-20140011827-A1 | PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | RAMP1 27/4885CALCRL 1/4885HCRTR1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.